<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00657865</url>
  </required_header>
  <id_info>
    <org_study_id>Ram_Gep_1</org_study_id>
    <secondary_id>2007-007276-41</secondary_id>
    <nct_id>NCT00657865</nct_id>
  </id_info>
  <brief_title>Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril</brief_title>
  <official_title>Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project investigates the effect of ACE-inhibition on cellular metabolism by gene
      expression profiling of human muscle tissue, obtained by biopsy prior to and after ramipril
      intake.

      This should contribute to our understanding of the pathomechanisms involved in diabetes and
      the clinical effect of ACE-inhibition on patients with diabetes/metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genome-wide gene expression measurements in skeletal muscle at baseline and in response to ramipril intake.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramipril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramipril</intervention_name>
    <description>oral intake</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Healthy defined as absence of relevant disease

          -  Caucasian

          -  Aged 18-45 years

          -  BMI: 18-28 kg/m2

          -  Signed informed consent

          -  Blood pressure between 110/45 and &lt;140/90 (twice at screening)

        Exclusion Criteria:

          -  History of renal artery stenosis

               -  angioneurotic edema

               -  psoriasis

               -  relevant renal diseases

          -  RR at screening &lt; 110/45 mmHg.

          -  Diabetes, history of hypertension, RR &gt; 140/90 at screening, cardiovascular disease

          -  Known Diabetes mellitus of parents

          -  HIV or Hepatitis B/C positive virology

          -  Allergy or hypersensitivity against ACE-inhibitors / ramipril or to xylocain

          -  Contraindications against the use of the drug according to the SmPC, history of
             angioedema

          -  Any drug intake 3 weeks prior to first study day

          -  History of excessive bleeding tendency / hemophilia

          -  Presence of relevant illness within the last 3 weeks

          -  Suspected non-compliance with study instructions and life-style requirements

          -  Alcohol or drug abuse

          -  Blood/Plasma donation within 4 weeks prior to study day

          -  Previous exposure to antihypertensive drugs, ACE-inhibitors, in particular ramipril

          -  Current smoking (any quantity), (at least 6 months of non-smoking required)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Mueller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dep. of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna, Department of Clinical Pharacology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <last_update_submitted>August 19, 2011</last_update_submitted>
  <last_update_submitted_qc>August 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Markus Mueller</investigator_full_name>
    <investigator_title>Prof. Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

